Search Results

You are looking at 11 - 18 of 18 items for :

  • Refine by access: All content x
Clear All
Conleth G Murphy Bons Secours Hospital Cork, Medical Oncology, Cork, Ireland
University College Cork, Medicine, Cork, Ireland

Search for other papers by Conleth G Murphy in
Google Scholar
PubMed
Close
and
Maura N Dickler Memorial Sloan-Kettering Cancer Center, Breast Medicine Service, New York, New York, USA
Joan and Sanford I Weill Medical College of Cornell University, Medicine, New York, New York, USA

Search for other papers by Maura N Dickler in
Google Scholar
PubMed
Close

progression-free survival (PFS) was seen between the three arms. Subsequent prospective–retrospective analysis of ESR1 mutation status in archival plasma circulating tumor DNA (ctDNA) indicated improved outcomes with fulvestrant compared with exemestane

Free access
Berna C Özdemir Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
International Cancer Prevention Institute, Epalinges, Switzerland

Search for other papers by Berna C Özdemir in
Google Scholar
PubMed
Close
,
George Sflomos ISREC – Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland

Search for other papers by George Sflomos in
Google Scholar
PubMed
Close
, and
Cathrin Brisken International Cancer Prevention Institute, Epalinges, Switzerland
ISREC – Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland

Search for other papers by Cathrin Brisken in
Google Scholar
PubMed
Close

prognostic significance ( Shao et al . 2015 ). During the last years, liquid biopsies referring to the analysis of circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) have been developed as surrogate markers to inform on tumor

Free access
Isabel Coutinho Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Isabel Coutinho in
Google Scholar
PubMed
Close
,
Tanya K Day Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Tanya K Day in
Google Scholar
PubMed
Close
,
Wayne D Tilley Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Close
, and
Luke A Selth Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia
Freemasons Foundation Centre for Men’s Health, School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Luke A Selth in
Google Scholar
PubMed
Close

(CTCs) and cell-free circulating tumor DNA (ctDNA) from patients with CRPC ( Antonarakis et al . 2014 , Carreira et al . 2014 , Azad et al . 2015 ). Although AR amplification is frequent in CRPC and an important driver of therapy resistance, AR

Free access
Jennifer R Eads Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Pennsylvania, USA

Search for other papers by Jennifer R Eads in
Google Scholar
PubMed
Close
,
Thorvardur R Halfdanarson Division of Medical Oncology, Mayo Clinic Cancer Center, Rochester, Minnesota, USA

Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Close
,
Tim Asmis Division of Medical Oncology, University of Ottawa, Ottawa, Ontario, Canada

Search for other papers by Tim Asmis in
Google Scholar
PubMed
Close
,
Andrew M Bellizzi Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

Search for other papers by Andrew M Bellizzi in
Google Scholar
PubMed
Close
,
Emily K Bergsland Department of Medicine, University of California, San Francisco, California, USA

Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Close
,
Arvind Dasari Division of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Close
,
Ghassan El-Haddad Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Close
,
Michael Frumovitz Division of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Search for other papers by Michael Frumovitz in
Google Scholar
PubMed
Close
,
Joshua Meyer Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Search for other papers by Joshua Meyer in
Google Scholar
PubMed
Close
,
Erik Mittra Division of Molecular Imaging and Therapy, Oregon Health & Science University, Portland, Oregon, USA

Search for other papers by Erik Mittra in
Google Scholar
PubMed
Close
,
Sten Myrehaug Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Search for other papers by Sten Myrehaug in
Google Scholar
PubMed
Close
,
Eric Nakakura Department of Surgery, University of California, San Francisco, California, USA

Search for other papers by Eric Nakakura in
Google Scholar
PubMed
Close
,
Nitya Raj Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Nitya Raj in
Google Scholar
PubMed
Close
,
Heloisa P Soares Division of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Salt Lake City, Utah, USA

Search for other papers by Heloisa P Soares in
Google Scholar
PubMed
Close
,
Brian Untch Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Brian Untch in
Google Scholar
PubMed
Close
,
Namrata Vijayvergia Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Search for other papers by Namrata Vijayvergia in
Google Scholar
PubMed
Close
, and
Jennifer A Chan Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Close

( Subbiah et al. 2022 ). Of note, the earlier NEN sequencing efforts have been conducted in tumor tissue specimens and work on circulating tumor specimens is limited and investigational. In the CIRCAN-NEC pilot study, circulating tumor DNA (ctDNA) was

Open access
S M Sadowski Endocrine Surgery, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, Maryland, USA

Search for other papers by S M Sadowski in
Google Scholar
PubMed
Close
,
C R C Pieterman Department of Surgical Oncology, Section of Surgical Endocrinology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by C R C Pieterman in
Google Scholar
PubMed
Close
,
N D Perrier Department of Surgical Oncology, Section of Surgical Endocrinology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Search for other papers by N D Perrier in
Google Scholar
PubMed
Close
,
F Triponez Thoracic and Endocrine Surgery and Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland

Search for other papers by F Triponez in
Google Scholar
PubMed
Close
, and
G D Valk Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by G D Valk in
Google Scholar
PubMed
Close

worse prognosis; however, this was determined in a cohort of metastatic NETs of all sites, not solely pancreatic NETs ( Khan et al. 2011 , 2013 ). Given the low mutational burden in pNET, use of circulating tumor DNA (ctDNA) as prognostic biomarker

Free access
Neil Portman The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

Search for other papers by Neil Portman in
Google Scholar
PubMed
Close
,
Sarah Alexandrou The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

Search for other papers by Sarah Alexandrou in
Google Scholar
PubMed
Close
,
Emma Carson The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

Search for other papers by Emma Carson in
Google Scholar
PubMed
Close
,
Shudong Wang Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, South Australia, Australia

Search for other papers by Shudong Wang in
Google Scholar
PubMed
Close
,
Elgene Lim The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

Search for other papers by Elgene Lim in
Google Scholar
PubMed
Close
, and
C Elizabeth Caldon The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia

Search for other papers by C Elizabeth Caldon in
Google Scholar
PubMed
Close

mutations. In the PALOMA-3 trial, fulvestrant plus palbociclib improved PFS in patients with ESR1 mutant and ESR1 WT circulating tumour DNA (ctDNA), indicating that CDK4/6 inhibitors are effective irrespective of ESR1 mutation status ( Fribbens et al

Free access
Suzan Stelloo Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Suzan Stelloo in
Google Scholar
PubMed
Close
,
Andries M Bergman Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Andries M Bergman in
Google Scholar
PubMed
Close
, and
Wilbert Zwart Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Department of Biomedical Engineering, Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands

Search for other papers by Wilbert Zwart in
Google Scholar
PubMed
Close

interesting approach, applicable for patients with large burden of ctDNA, could be identification of nucleosome footprints in ctDNA. Analysis of two plasma samples taken 12 months apart, during which the prostate adenocarcinoma transdifferentiated to a

Free access
Elgene Lim Garvan Institute of Medical Research and St Vincent’s Hospital, University of New South Wales, Sydney, New South Wales, Australia

Search for other papers by Elgene Lim in
Google Scholar
PubMed
Close
,
Gerard Tarulli Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Gerard Tarulli in
Google Scholar
PubMed
Close
,
Neil Portman Garvan Institute of Medical Research and St Vincent’s Hospital, University of New South Wales, Sydney, New South Wales, Australia

Search for other papers by Neil Portman in
Google Scholar
PubMed
Close
,
Theresa E Hickey Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Theresa E Hickey in
Google Scholar
PubMed
Close
,
Wayne D Tilley Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, University of Adelaide, Adelaide, South Australia, Australia

Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Close
, and
Carlo Palmieri Institute of Translational Medicine, University of Liverpool, Clatterbridge Cancer Centre, NHS Foundation Trust, and Royal Liverpool University Hospital, Liverpool, Merseyside, UK

Search for other papers by Carlo Palmieri in
Google Scholar
PubMed
Close

status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2− advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 tria

Free access